DYRK1A As A Novel Target For Glioblastoma Therapies
Funder
National Health and Medical Research Council
Funding Amount
$620,294.00
Summary
Glioblastoma is a form of brain cancer that is currently incurable. We have discovered that switching-off an enzyme called DYRK1A (using ‘DYRK1A inhibitors’) kills glioblastoma cells. This therapeutic advantage is even greater when combined with drugs approved for other cancers. This project will develop new DYRK1A inhibitors and examine a novel combination treatment for glioblastoma patients. This could initiate a novel therapy that could significantly extend patients’ lives.
Control of immune recognition and response by microbial metabolites. This project aims to study immune recognition of microbial metabolites and develop reagents to control immune responses. Chemical synthesis will be used to develop new antigens for unconventional T cells and the first soluble agonists and antagonists of a glycolipid-sensing immune receptor. Expected outcomes include the discovery of new immune effectors, broadening our knowledge of the repertoire of small molecules that can be ....Control of immune recognition and response by microbial metabolites. This project aims to study immune recognition of microbial metabolites and develop reagents to control immune responses. Chemical synthesis will be used to develop new antigens for unconventional T cells and the first soluble agonists and antagonists of a glycolipid-sensing immune receptor. Expected outcomes include the discovery of new immune effectors, broadening our knowledge of the repertoire of small molecules that can be sensed by the immune system, and developing chemical approaches to promote or dampen immune responses. Major benefits include research training in chemical biology, strengthened international linkages and fundamental insights into the chemical basis of immune recognition and response.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE140100162
Funder
Australian Research Council
Funding Amount
$374,005.00
Summary
Enzymatic synthesis of pro-resolution lipid mediators: Towards new therapeutic strategies for inflammatory diseases. Inflammation is a major contributing factor in many diseases, including arthritis, Alzheimer's disease, multiple sclerosis, cardiovascular disease and cancer. It has recently been shown that the resolution of inflammation is an active biological process initiated by lipid mediators. The aim of this project is to synthesise and characterise pro-resolution lipid mediators, elucidate ....Enzymatic synthesis of pro-resolution lipid mediators: Towards new therapeutic strategies for inflammatory diseases. Inflammation is a major contributing factor in many diseases, including arthritis, Alzheimer's disease, multiple sclerosis, cardiovascular disease and cancer. It has recently been shown that the resolution of inflammation is an active biological process initiated by lipid mediators. The aim of this project is to synthesise and characterise pro-resolution lipid mediators, elucidate the enzyme cascades involved in their biosynthesis and explore their roles in the active resolution of inflammation. This project will provide a fundamental understanding of pro-resolution and anti-inflammatory pathways as well as new therapeutic target molecules for the treatment of inflammatory diseases.Read moreRead less
Unravelling the immunology of complex glycolipids by chemical synthesis. This project seeks to develop new approaches to chemically synthesise bacterial and fungal glycolipids and develop a molecular-level understanding of their effect on the immune system. Bacterial and fungal glycolipids are exotic chemical species that act as danger signals to prime and modulate our innate immune responses. These complex glycolipids possess powerful immunological activities that continue to shape our understa ....Unravelling the immunology of complex glycolipids by chemical synthesis. This project seeks to develop new approaches to chemically synthesise bacterial and fungal glycolipids and develop a molecular-level understanding of their effect on the immune system. Bacterial and fungal glycolipids are exotic chemical species that act as danger signals to prime and modulate our innate immune responses. These complex glycolipids possess powerful immunological activities that continue to shape our understanding of innate immunity, yet cannot be acquired from natural sources in the quantities and purity needed. The approaches expected to be developed in the project will be used to illuminate molecular details of immune signalling through pattern recognition receptors and presentation on specialised glycolipid antigen-presenting molecules. Outcomes may include new ways to fight disease and promote health by marshalling the resources of the immune system.Read moreRead less
Lymphotropic prodrugs: a novel mechanism for targeted drug delivery. This project aims to design chemically modified drugs that target drug delivery specifically to white blood cells. This approach promises to maximise drug action and simultaneously reduce toxicity for diseases where lymphocytes are the major drug target. These include autoimmune disease, leukaemia, lymphoma, HIV, transplant rejection and diabetes.